272 related articles for article (PubMed ID: 32156064)
1. Recent Small-Molecule Inhibitors of the p53-MDM2 Protein-Protein Interaction.
Beloglazkina A; Zyk N; Majouga A; Beloglazkina E
Molecules; 2020 Mar; 25(5):. PubMed ID: 32156064
[TBL] [Abstract][Full Text] [Related]
2. Targeting MDM2-p53 interaction for cancer therapy: are we there yet?
Nag S; Zhang X; Srivenugopal KS; Wang MH; Wang W; Zhang R
Curr Med Chem; 2014; 21(5):553-74. PubMed ID: 24180275
[TBL] [Abstract][Full Text] [Related]
3. Natural product MDM2 inhibitors: anticancer activity and mechanisms of action.
Qin JJ; Nag S; Voruganti S; Wang W; Zhang R
Curr Med Chem; 2012; 19(33):5705-25. PubMed ID: 22830335
[TBL] [Abstract][Full Text] [Related]
4. Molecular interaction fields and 3D-QSAR studies of p53-MDM2 inhibitors suggest additional features of ligand-target interaction.
Dezi C; Carotti A; Magnani M; Baroni M; Padova A; Cruciani G; Macchiarulo A; Pellicciari R
J Chem Inf Model; 2010 Aug; 50(8):1451-65. PubMed ID: 20726601
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction.
Zhuang C; Miao Z; Zhu L; Zhang Y; Guo Z; Yao J; Dong G; Wang S; Liu Y; Chen H; Sheng C; Zhang W
Eur J Med Chem; 2011 Nov; 46(11):5654-61. PubMed ID: 21996465
[TBL] [Abstract][Full Text] [Related]
6. Targeting the MDM2-p53 protein-protein interaction with prenylchalcones: Synthesis of a small library and evaluation of potential antitumor activity.
Brandão P; Loureiro JB; Carvalho S; Hamadou MH; Cravo S; Moreira J; Pereira D; Palmeira A; Pinto M; Saraiva L; Cidade H
Eur J Med Chem; 2018 Aug; 156():711-721. PubMed ID: 30041135
[TBL] [Abstract][Full Text] [Related]
7. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.
Gupta AK; Bharadwaj M; Kumar A; Mehrotra R
Top Curr Chem (Cham); 2017 Feb; 375(1):3. PubMed ID: 27943171
[TBL] [Abstract][Full Text] [Related]
8. Small-molecule MDM2-p53 inhibitors: recent advances.
Zhang B; Golding BT; Hardcastle IR
Future Med Chem; 2015; 7(5):631-45. PubMed ID: 25921402
[TBL] [Abstract][Full Text] [Related]
9. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
Zhao Y; Aguilar A; Bernard D; Wang S
J Med Chem; 2015 Feb; 58(3):1038-52. PubMed ID: 25396320
[TBL] [Abstract][Full Text] [Related]
10. A yeast two-hybrid system for the screening and characterization of small-molecule inhibitors of protein-protein interactions identifies a novel putative Mdm2-binding site in p53.
Wong JH; Alfatah M; Sin MF; Sim HM; Verma CS; Lane DP; Arumugam P
BMC Biol; 2017 Nov; 15(1):108. PubMed ID: 29121928
[TBL] [Abstract][Full Text] [Related]
11. Recent advances on the intervention sites targeting USP7-MDM2-p53 in cancer therapy.
Harakandi C; Nininahazwe L; Xu H; Liu B; He C; Zheng YC; Zhang H
Bioorg Chem; 2021 Nov; 116():105273. PubMed ID: 34474304
[TBL] [Abstract][Full Text] [Related]
12. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
Sirous H; Chemi G; Campiani G; Brogi S
Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
[TBL] [Abstract][Full Text] [Related]
13. Design of libraries targeting protein-protein interfaces.
Fry D; Huang KS; Di Lello P; Mohr P; Müller K; So SS; Harada T; Stahl M; Vu B; Mauser H
ChemMedChem; 2013 May; 8(5):726-32. PubMed ID: 23436619
[TBL] [Abstract][Full Text] [Related]
14. p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents.
Nayak SK; Khatik GL; Narang R; Monga V; Chopra HK
Curr Cancer Drug Targets; 2018; 18(8):749-772. PubMed ID: 28669344
[TBL] [Abstract][Full Text] [Related]
15. Small-molecule inhibitors of p53-MDM2 interaction: the 2006-2010 update.
Millard M; Pathania D; Grande F; Xu S; Neamati N
Curr Pharm Des; 2011; 17(6):536-59. PubMed ID: 21391905
[TBL] [Abstract][Full Text] [Related]
16. How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures.
Estrada-Ortiz N; Neochoritis CG; Dömling A
ChemMedChem; 2016 Apr; 11(8):757-72. PubMed ID: 26676832
[TBL] [Abstract][Full Text] [Related]
17. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer.
Patel S; Player MR
Expert Opin Investig Drugs; 2008 Dec; 17(12):1865-82. PubMed ID: 19012502
[TBL] [Abstract][Full Text] [Related]
18. Small molecule agents targeting the p53-MDM2 pathway for cancer therapy.
Wang W; Hu Y
Med Res Rev; 2012 Nov; 32(6):1159-96. PubMed ID: 23059763
[TBL] [Abstract][Full Text] [Related]
19. Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
He S; Dong G; Wu S; Fang K; Miao Z; Wang W; Sheng C
J Med Chem; 2018 Aug; 61(16):7245-7260. PubMed ID: 30045621
[TBL] [Abstract][Full Text] [Related]
20. Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed.
Zanjirband M; Rahgozar S
Curr Drug Targets; 2019; 20(11):1091-1111. PubMed ID: 30947669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
